Review anchor
Phosphodiesterase 3A
SINGLE PROTEIN · Sus scrofa
As of 2026-09-13
Evidence Snapshot
Phosphodiesterase 3A
CHEMBL3061
SINGLE PROTEIN
Sus scrofa
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Phosphodiesterase 3A as ChEMBL target CHEMBL3061, mapped to UniProt Q9XSW7. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL3061
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9XSW7
Phosphodiesterase
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Phosphodiesterase 3A matters
Phosphodiesterase 3A is reviewed as Phosphodiesterase (UniProt Q9XSW7); the current evidence base includes 2 approved drugs, 12 compounds, and 11 assays, with lead potency reaching pChEMBL 6.4.
Protein context
Phosphodiesterase
Phosphodiesterase Sequence length is 985 aa.
Review this target as Phosphodiesterase 3A, mapped to UniProt Q9XSW7. ChEMBL maps the protein component as Phosphodiesterase. Sequence length is 985 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q9XSW7
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 2 approved drugs, 12 compounds, and 11 assays for this target. The dominant activity type is IC50. CHEMBL302299 is the current potency anchor at pChEMBL 6.4.
Use CHEMBL302299 as the tractability anchor when discussing potency (pChEMBL 6.4).
Activity source · ChEMBL 36 via Core Engine
2 approved
pChEMBL 6.4
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Phosphodiesterase 3A matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9XSW7, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
12
Total Compounds
11
Total Assays
2
Approved Drugs
IC50: 16.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL302299
|
6.4 | IC50 | — |
|
|
No preferred name
CHEMBL19224
|
6.2 | IC50 | Clinical |
|
|
No preferred name
CHEMBL189
|
6.1 | IC50 | Approved |
|
|
No preferred name
CHEMBL545712
|
4.8 | IC50 | — |
|
|
No preferred name
CHEMBL932
|
4.4 | IC50 | Approved |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
MILRINONE
CHEMBL189
|
1987 |
Source Header